Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Urothelial Carcinoma in Situ”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 10 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT01625260
What this trial is testing

ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer

Who this might be right for
Non-muscle Invasive Bladder Cancer
Altor BioScience 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT05241340
What this trial is testing

Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer

Who this might be right for
Urothelial Carcinoma Bladder
The Methodist Hospital Research Institute 33
Testing effectiveness (Phase 2)Study completedNCT00003129
What this trial is testing

Chemotherapy in Treating Patients With Early-Stage Bladder Cancer

Who this might be right for
Bladder Cancer
Eastern Cooperative Oncology Group 75
Large-scale testing (Phase 3)Study completedNCT00406068
What this trial is testing

Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder Neoplasms
Bioniche Life Sciences Inc. 129
Early research (Phase 1)Ended earlyNCT05014139
What this trial is testing

Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

Who this might be right for
Urinary Bladder NeoplasmsCarcinoma in SituCarcinoma Transitional Cell+2 more
Astellas Pharma Global Development, Inc. 37
Large-scale testing (Phase 3)Study completedNCT01442519
What this trial is testing

Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder Cancer

Who this might be right for
Bladder Cancer
University of Rome Tor Vergata 212
Early research (Phase 1)UnknownNCT00109655
What this trial is testing

Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure

Who this might be right for
Carcinoma, Transitional CellBladder Neoplasms
Cell Genesys 75
Not applicableStudy completedNCT02986867
What this trial is testing

SAbR Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical Carcinoma

Who this might be right for
Urothelial CarcinomaMelanomaCervical Carcinoma in Situ
University of Texas Southwestern Medical Center 27
Large-scale testing (Phase 3)Ended earlyNCT01310803
What this trial is testing

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

Who this might be right for
Carcinoma in SituTransitional Cell CarcinomaNon-muscle Invasive Bladder Cancer
Endo USA Inc., a Keenova Therapeutics Company 1
Testing effectiveness (Phase 2)Study completedNCT00023842
What this trial is testing

BCG With or Without Mitomycin in Treating Patients With Bladder Cancer

Who this might be right for
Bladder Cancer
European Organisation for Research and Treatment of Cancer - EORTC 97